Greek Cannabis Study Provides Encouraging News For Patients With Neurological Disorders
Neurological disorders are serious medical conditions that affect the human brain as well as the nerves found throughout the human body and the spinal cord. Examples of neurological disorders include, but are not limited to:
- Alzheimer disease
- Multiple sclerosis
- Parkinson’s disease
- Brain tumours
Researchers in Greece recently examined the relationship between cannabis and neurological disorders and the results of their research were favorable. Below is more information about it via a news release from NORML:
Athens, Greece: Patients diagnosed with neurological disorders (e.g., epilepsy, Parkinson’s disease, etc.) experience improvements in their symptoms following medical cannabis treatment, according to data published in the journal Advances in Experimental Medicine and Biology.
A team of Greek scientists assessed cannabis use in a cohort of 100 patients. Patients’ quality of life was assessed via the use of a 36-item health survey.
Researchers reported: “The majority of our patients who received medical cannabis to treat their neurological disorders (58 percent) reported decrease in their symptoms, [including] better energy and vitality … and an improvement in sleeping and appetite after receiving medical cannabis. … Participants, who reported a longer period of receiving medical cannabis, reported statistically significant more energy and vitality, but also better mental and general health status.”
Data published earlier this year similarly reported that the use of plant-derived cannabis oils containing balanced ratios of THC and CBD is safe and effective for older patients suffering from certain treatment-resistant neurological diseases, including Parkinson’s, multiple sclerosis, and peripheral neuropathy.
Full text of the study, “Quality of life in patients receiving medical cannabis,” appears in Advances in Experimental Medicine and Biology. Additional information on the use of cannabis for the treatment of neurological disorders is available from NORML’s publication, Clinical Applications for Cannabis and Cannabinoids.